GLP-1 agonist's beyond-the-pill ecosystem opportunity — the extraordinary commercial success of GLP-1 receptor agonists for obesity treatment — semaglutide (Ozempic/Wegovy, Novo Nordisk) and tirzepatide (Mounjaro/Zepbound, Eli Lilly) generating combined revenue exceeding $25 billion in 2023 — creating commercial motivation for beyond-the-pill ecosystem development that...